CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company is headquartered in Saratoga, California.
| Revenue (TTM) | $13.89M |
| Gross Profit (TTM) | $7.07M |
| EBITDA | $-29.57M |
| Operating Margin | -208.10% |
| Return on Equity | -335.10% |
| Return on Assets | -132.50% |
| Revenue/Share (TTM) | $0.29 |
| Book Value | $0.26 |
| Price-to-Book | 24.45 |
| Price-to-Sales (TTM) | 25.47 |
| EV/Revenue | 22.57 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 9.90% |
| Shares Outstanding | $53.21M |
| Float | $27.98M |
| % Insiders | 30.14% |
| % Institutions | 9.74% |
Volatility is currently expanding
AI-assisted reading tool designed to aid physician review of small bowel capsule endoscopy studies performed due to suspected bleeding using the CapsoCam Plus® system AI-assisted reading tool designed to aid physician review of small bowel capsule endoscopy studies performed due to suspected bleeding using the CapsoCam Plus® system
SARATOGA, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that Johnny Wang, President and Chief Executive Officer, David Garcia, Senior Vice President of Finance, and Doug Atkinson, Senior Vice President of Global Sales, plan to participate in the following upcoming investor conferences: H.C.
SARATOGA, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported financial results and provided a business update for its second quarter ended June 30, 2026.
AI-assisted review feature designed to support physician review of small bowel capsule endoscopy studies using the CapsoCam Plus® system AI-assisted review feature designed to support physician review of small bowel capsule endoscopy studies using the CapsoCam Plus® system
SARATOGA, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that the Company will release second quarter 2026 financial results on Thursday, August 13, 2026, after the close of market.
SARATOGA, Calif., July 02, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (Nasdaq: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, announced the appointment of David S.
SARATOGA, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported financial results for its first quarter ended March 31, 2026.
SARATOGA, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that the Company will release first quarter 2026 financial results on Thursday, May 14, 2026, after the close of market. CapsoVision will host a corresponding conference call and a live webcast at 1:30 pm PT / 4:30 pm ET on the same day to discuss the results and provide a corporate update.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on CV and any ticker you trade — then tracks every position and per-strategy win rate.
